1. Home
  2. GTEC vs BIVI Comparison

GTEC vs BIVI Comparison

Compare GTEC & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Greenland Technologies Holding Corporation

GTEC

Greenland Technologies Holding Corporation

HOLD

Current Price

$0.54

Market Cap

13.4M

Sector

Industrials

ML Signal

HOLD

Logo BioVie Inc.

BIVI

BioVie Inc.

HOLD

Current Price

$2.18

Market Cap

13.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GTEC
BIVI
Founded
2006
2013
Country
United States
United States
Employees
340
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.4M
13.3M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
GTEC
BIVI
Price
$0.54
$2.18
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
72.8K
177.7K
Earning Date
05-15-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$1.62
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.01
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.47
$1.06
52 Week High
$2.06
$9.09

Technical Indicators

Market Signals
Indicator
GTEC
BIVI
Relative Strength Index (RSI) 40.17 64.39
Support Level $0.52 $1.22
Resistance Level $0.73 N/A
Average True Range (ATR) 0.04 0.22
MACD -0.00 0.02
Stochastic Oscillator 9.73 80.36

Price Performance

Historical Comparison
GTEC
BIVI

About GTEC Greenland Technologies Holding Corporation

Greenland Technologies Holding Corp is a developer of quality solutions in the material handling industry. It is a transmission and drivetrain systems provider for material handling equipment such as forklift trucks for industrial and logistic applications. Geographically, the company has its presence in Domestic and International markets and earns majority of the revenue from Domestic Sales.

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Share on Social Networks: